Gynazole 1 Butoconazole Vaginal Cream Recalled for Formulation Error
Padagis US LLC is recalling Gynazole 1 butoconazole nitrate vaginal cream nationwide due to a manufacturing error where hydrophilic colloidal silica was used instead of hydrophobic colloidal silica.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall. Manufacturing formulation error involving an incorrect chemical ingredient in a drug product constitutes a risk-of-harm situation, fitting the rubric criterion for this score.
Plain-English summary
Padagis US LLC is recalling Gynazole 1 (butoconazole nitrate 2%) vaginal cream due to a manufacturing formulation error. The product was manufactured using hydrophilic colloidal silica instead of hydrophobic colloidal silica as required by the manufacturing process.
The recall involves 10,512 cartons with Lot #164185 (expiration April 2024), distributed nationwide in the United States. Gynazole 1 is a prescription vaginal antifungal cream.
The recalled product
- Product
- GYNAZOLE 1 (BUTOCONAZOLE NITRATE)
- Brand
- GYNAZOLE 1
- Manufacturer
- Padagis US LLC
- Category
- Drug — Vaginal Antifungal
- Hazard
- formulation-error
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 164185
- Exp. Date 4/2024
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01